Advertisement

Pharmaceutical Medicine

, Volume 25, Issue 4, pp 269–277 | Cite as

Journal Watch

Update
  • 13 Downloads

Contents

  • 1. Reflections on the Changing Face of German Pharmaceutical Policy: How Far is Germany from Value-Based Pricing?

  • 2. The Appropriate Elicitation of Expert Opinion in Economic Models: Making Expert Data Fit for Purpose

  • 3. Prioritizing Comparative Effectiveness Research: Are Drug and Implementation Trials Equally Worth Funding?

  • 4. Presenting Evidence and Summary Measures to Best Inform Societal Decisions When Comparing Multiple Strategies

  • 5. Association between Leukotriene-Modifying Agents and Suicide: What is the Evidence?

  • 6. The Risk of Ischaemic Colitis in Irritable Bowel Syndrome Patients Treated with Serotonergic Therapies

  • 7. Quinolones: Review of Psychiatric and Neurological Adverse Reactions

  • 8. Neovascular Age-Related Macular Degeneration: Opportunities for Development of First-in-Class Biopharmaceuticals

  • 9. Great Expectations: What Do Patients Using Complementary and Alternative Medicine Hope For?

  • 10. Unit Costs for Delivery of Antiretroviral Treatment and Prevention of...

References

Reference

  1. Gerber A, Stock S, Dintsios C-M. Reflections on the changing face of German pharmaceutical policy: how far is Germany from value-based pricing? [editorial]. Pharmacoeconomics 2011; 29 (7): 549–53PubMedCrossRefGoogle Scholar

Reference

  1. Sullivan W, Payne K. The appropriate elicitation of expert opinion in economic models: making expert data fit for purpose. Pharmacoeconomics 2011; 29 (6): 455-9 Gandjour A. Prioritizing comparative effectiveness research: are drug and implementation trials equally worth funding? Pharmacoeconomics 2011; 29 (7): 555–61Google Scholar

Reference

  1. Eckermann S, Willan AR. Presenting evidence and summary measures to best inform societal decisions when comparing multiple strategies. Pharmacoeconomics 2011; 29 (7): 563–77PubMedGoogle Scholar

Reference

  1. Schumock GT, Lee TA, Joo MJ, et al. Association between leukotriene-modifying agents and suicide: what is the evidence? Drug Saf 2011; 34 (7): 533–44PubMedCrossRefGoogle Scholar

Reference

  1. Lewis JH. The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies. Drug Saf 2011; 34 (7): 545–65PubMedCrossRefGoogle Scholar

Reference

  1. Tomé AM, Filipe A. Quinolones: review of psychiatric and neurological adverse reactions. Drug Saf 2011; 34 (6): 465–88PubMedCrossRefGoogle Scholar

Reference

  1. Schiffelers RM, van der Vaart TK, Storm G. Neovascular age-related macular degeneration: opportunities for development of first-in-class biopharmaceuticals. Biodrugs 2011; 25 (3): 171–89PubMedCrossRefGoogle Scholar

Reference

  1. Ernst E, Hung SK. Great expectations: what do patients using complementary and alternative medicine hope for? Patient 2011; 4 (2): 89–101PubMedCrossRefGoogle Scholar

Reference

  1. Galárraga O, Wirtz V, Figueroa-Lara A, et al. Unit costs for delivery of antiretroviral treatment and prevention of mother-to-child transmission of HIV: a systematic review for low- andmiddle-income countries. Pharmacoeconomics 2011; 29 (7): 579–99PubMedGoogle Scholar

Reference

  1. Stafinski T, Menon D, Philippon DJ, et al. Health technology funding decisionmaking processes around the world: the same, yet different. Pharmacoeconomics 2011; 29 (6): 475–95PubMedCrossRefGoogle Scholar

Reference

  1. Hoggatt J. Hot ortho-biologic topics at AAOS 2011: platelet-rich plasma and related growth factors generate excitement. Biodrugs 2011; 25 (3): 197–202PubMedCrossRefGoogle Scholar

Reference

  1. Théophile H, Schaeverbeke T, Miremont-Salamé G, et al. Sources of information on lymphoma associated with anti-tumour necrosis factor agents: comparison of published case reports and cases reported to the French pharmacovigilance system. Drug Saf 2011; 34 (7): 577–85PubMedCrossRefGoogle Scholar

Reference

  1. van Dijk-de Vries AN, Duimel-Peeters IGP, Vrijhoef HJM. An instrument to assess the needs of patients with type 2 diabetes mellitus for health-promotion activities. Patient 2011; 4 (2): 115–23PubMedCrossRefGoogle Scholar

Reference

  1. Diaby V, Dié Kakou H, Lachaine J. Eliciting preferences for reimbursed drugs selection criteria in Côte d’Ivoire. Patient 2011; 4 (2): 125–31PubMedCrossRefGoogle Scholar

Reference

  1. Iskedjian M, Covert DW, Walker JH. Persistence with prostaglandin agonist use with and without adjunctive therapy for glaucoma patients: a Canadian populationbased analysis. Patient 2011; 4 (2): 133–41PubMedCrossRefGoogle Scholar

Reference

  1. Krol M, Papenburg J, Koopmanschap M, et al. Do productivity costs matter? The impact of including productivity costs on the incremental costs of interventions targeted at depressive disorders. Pharmacoeconomics 2011; 29 (7): 601–19PubMedGoogle Scholar

Reference

  1. Leidl R, Reitmeir P. A value set for the EQ-5D based on experienced health states: development and testing for the German population. Pharmacoeconomics 2011; 29 (6): 521–34PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2011

Personalised recommendations